Trial | NCT00528710  Report issue

Title

Efficacy of S-Adenosylmethionine in Fibromyalgia
Double-Blind, Placebo-Controlled Trial of the Impact of S-Adenosyl-L-Methionine (SAM-e) on the Mood and Other Symptoms in Fibromyalgia

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    70
Fundamentally, the trial aims to conduct a gold-standard test of the clinical impact of SAM-e in the treatment of depressed mood and general symptoms of fibromyalgia (FMS).

As such, salient clinical and pathological parameters will be assessed over an 8-week period in 60 patients who will be provided with either SAM-e or a placebo preparation . On the basis of previous literature, it is hypothesised that patients in the active treatment group will experience moderate but significant improvements across the clinical measures, and that these gains will be significantly greater than any reported in the placebo group. All patients will provide informed consent. All procedures will be conducted under medical supervision and the preparation itself is very safe when used in the manner proposed for the trial
Study Started
Nov 30
2006
Study Completion
Mar 31
2007
Last Update
Sep 12
2007
Estimate

Dietary Supplement SAM-e (S-Adenosyl-L-Methionine)

One 400 mg tablet daily in the morning.

P Placebo Comparator

Placebo Control Group

Criteria 

Inclusion Criteria:

Diagnosis of Fibromyalgia by a medical practitioner

Exclusion Criteria:

Pregnancy, Manic and hypomanic conditions
No Results Posted